Examiners Amendment

United States Patent and Trademark Office (USPTO)

Office Action (Official Letter) About Applicant’s Trademark Application

 

 

 

EXAMINER’S AMENDMENT

 

 

Issue date:  July 08, 2019

 

 

USPTO database searched; no conflicting marks found.  The trademark examining attorney searched the USPTO database of registered and pending marks and found no conflicting marks that would bar registration under Trademark Act Section 2(d).  15 U.S.C. §1052(d); TMEP §704.02.

 

Application has been amended as shown below.  As agreed to by Jeffrey H. Handelsman

on July 1, 2019, the examining attorney has amended the application as shown below.  Please notify the examining attorney immediately of any objections.  TMEP §707.  Otherwise, no response is required.  Id.  In addition, applicant is advised that amendments to the goods and/or services are permitted only if they clarify or limit them; amendments that add to or broaden the scope of the goods and/or services are not permitted.  37 C.F.R. §2.71(a).

 

AMENDMENT TO IDENTFICATION OF GOODS

 

            The identification of goods is amended to read as follows:

 

Class 5 - Pharmaceutical and medicated preparations for use in nephrology, neurology, oncology, urology, andrology and cardiology, and for use in the treatment of nasal allergies, respiratory allergies, and for use as anti-infectives; contraceptive preparations; dietary and nutritional supplements; prenatal vitamins; pharmaceutical products for the treatment of bone diseases; preparations for the suppression of hormones; pharmaceutical preparations and substances directed to women's health for use in the treatment, alleviation and prevention of overactive bladder, female sexual dysfunction, infertility, endometriosis, vaginitis, osteoporosis/osteopenia, pelvic pain, dyspareunia, and candidiasis; all of the aforesaid goods not for use as a product name of a pharmaceutical product, in International Class 5

 

DISCLAIMER

 

The following disclaimer statement is added to the record:

 

            No claim is made to the exclusive right to use “PHARMACEUTICALS” apart from the mark as shown.

 

See 15 U.S.C. §1056(a); TMEP §§1213, 1213.08(a)(i).

 

SIGNIFICANCE OF THE TERM SEBELA

 

The following statement is added to the record:

 

            The wording “SEBELA” has no meaning other than trademark significance.

 

See 37 C.F.R. §2.61(b); TMEP §808.01(a).

 

TRANSLATION

 

The following statement is added to the record:

 

            The wording “SEBELA” has no meaning in a foreign language.

 

See 37 C.F.R. §2.61(b); TMEP §809.03.

 

 

 

 

 

 

 

/William H. Dawe, III/

Examining Attorney

Law Office 108

(571) 272-9337 voice

(571) 273-9337 fax

Bill.Dawe@USPTO.GOV (not for fomal responses)

 

 

United States Patent and Trademark Office (USPTO)

 

USPTO OFFICIAL NOTICE

 

Office Action (Official Letter) has issued

on July 08, 2019 for

U.S. Trademark Application Serial No. 88371925

 

Your trademark application has been reviewed by a trademark examining attorney.  As part of that review, the assigned attorney has issued an official letter.  Please follow the steps below.

 

(1)  Read the official letter.  No response is necessary.

 

(2)  Direct questions about the contents of the Office action to the assigned attorney below. 

 

/William H. Dawe, III/

Examining Attorney

Law Office 108

(571) 272-9337 voice

(571) 273-9337 fax

Bill.Dawe@USPTO.GOV (not for fomal responses)

 

Direct questions about navigating USPTO electronic forms, the USPTO website, the application process, the status of your application, and/or whether there are outstanding deadlines or documents related to your file to the Trademark Assistance Center (TAC).

 

 

 

GENERAL GUIDANCE

·       Check the status of your application periodically in the Trademark Status & Document Retrieval (TSDR) database to avoid missing critical deadlines.

 

·       Update your correspondence email address, if needed, to ensure you receive important USPTO notices about your application.

 

·       Beware of misleading notices sent by private companies about your application.  Private companies not associated with the USPTO use public information available in trademark registrations to mail and email trademark-related offers and notices – most of which require fees.  All official USPTO correspondence will only be emailed from the domain “@uspto.gov.”